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Though a  number of investigators have studied the appearance of 
antibody and agglutinin during pneumococcus  infection in man and in 
animals, it has seemed desirable to pursue the matter further.  For 
this purpose, we have used blood obtained from patients with Types 
I, II and III pneumococcus  pneumonia at the Massachusetts General 
Hospital and from the private practice of one of us.  Through the 
kindness of Dr. H. A. Christian of the Peter Bent Brigham Hospital 
and Dr. W. H. Robey and his associates of the Boston City Hospital, 
we have also had the opportunity to investigate the blood of patients 
in  these institutions.  We  are  especially indebted to  Dr.  Maxwell 
Finland of the Boston City Hospital and to Dr. George Walker of the 
Peter Bent Brigham Hospital for obtaining blood from patients in 
these  hospitals.  We  are  indebted  to  Dr.  Lloyd D.  Felton  of  the 
Harvard  Medical  School  for  his  kindness  in  furnishing  virulent 
cultures of the pneumococcus  and for many helpful suggestions. 
Method 
Tests for antibody were made by inoculating intraperitoneally each of 14  mice 
with 0.2 co. of the patient's serum plus 0.3 co. of one per cent peptone solution,  and 
directly after this with dilutions of a highly virulent culture of pneumoeoccus of 
the same type as that found to be the cause of the pneumonia.  For this purpose, 
seven dilutions of an eighteen hour beef heart broth culture of the organisms were 
made as follows:--i : 100, 1 : 1000, 1 : 10,000, 1 : 100,000, 1 : 1,000,000,  1 : 10,000,000 
* This investigation  was made with assistance from the Proctor Fund of Harvard 
University, the Committee on Therapeutic Research, Council on Pharmacy and 
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York. 
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and 1 : 100,000,000 and 0.5 cc. of each of these dilutions injected into each of two 
mice. 
The tests for antibody were thus done in duplicate.  In addition, no serum was 
given to two mice used as controls, one receiving 0.5 cc. of 1:10,000,000  and the 
other the same amount of 1 : 100,000,000 dilution of the culture.  All  mice were 
observed for 96 hours.  We have regarded the  survival of 1 mouse of the series 
inoculated with the patient's serum and organisms as an indication of protection. 
This seems reasonable in view of the death of the control mice and the fact  that 
in all patients whose blood was tested before treatment within the first 5 days of 
the illness no protection was found.  We realize a possibility of error in this, but 
such error would change the finding in only 3 out of 57 patients. 
Tests for agglutinin were made with suspensions  of living or dead homologous 
pneumococci at varying dilutions  (1:2,  1:4,  1:8,  1:16,  1:20,  1:40,  1:80,  l:100, 
1:200.  1:500)  of the patient's serum according to the method of Arlyle Noble 
(3". Bact., 14, 287, Nov., 1927), who uses small amounts of serum and concentrated 
suspensions  of organisms.  It was found that the tests were easier to read after a 
half hour of incubation, and this variation in the technique was made. 
The  blood of 57  patients  was investigated  for both  antibody  and 
agglutinin.  On 46 of the series from two to fifteen tests were made. 
In the  specifically treated  cases the  first  sample of blood was taken 
before serum was given.  Blood for subsequent  tests on these  cases 
was  taken  not  sooner than  eight  hours  after  the  administration  of 
serum.  Only 1 observation was made on 11 patients. 
The results may be sketched as follows :- 
Observations on Antibody in Pneumonia 
Time of appearance of antibody during the disease 
Our observations confirm those of other investigators in the finding 
that antibody in untreated  cases appears at or about the time of the 
fall in the temperature.  Of 4.9 patients to whom no serum had been 
given to the time the test was made none were found to have protection 
before the sixth day.  Of 6 patients not treated with serum and tested 
at  the  time of the  temperature  fall only  1  failed  to  show  antibody. 
The earliest time of appearance in the untreated group was the sixth 
day in 2 patients in whom the temperature fell within the next twenty- 
four hours. 
In the treated group protective substances were frequently demon- 
strated after the use of Felton's antibody at a time in the course of the 
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Behavior of A ntibody during Convalescence and in Complicated Cases 
Nineteen patients with antibody at the time of the fall in tempera- 
ture were tested during convalescence.  Protection was present in 
8 from a few days to a week, in 2 into the second week, in 3 into the 
third, in 4 into the fourth, in 1 into the fifth and in 1 into the ninth 
week.  In 11 of these cases no further tests were made.  The remain- 
ing 8 showed that the antibody, previously present, was absent in 2 
in the first, in 1 in the second, in 2 in the third, in 2 in the fifth and in 1 
in the eighth week. 
Four other patients who had had pneumonia 7 to 13 months pre- 
viously, but had not been tested during the course of the disease, 
failed to show antibody. 
In addition to the patients already referred to,  1 with unresolved 
pneumonia was found to have protection from the fifth to at least the 
forty-ninth day after the onset of the  disease.  His  febrile course 
lasted  43  days.  One  patient  with  pneumonia  and  empyema was 
first  tested  3  weeks  after the  estimated onset  of  the  illness.  At 
this time, he had antibody which persisted for at least four weeks 
longer.  Another patient had empyema following pneumonia and had 
developed antibody when first tested, but died three days later of 
pneumococcus endocarditis,  eighty-six days after the  onset of the 
illness. 
In our small series the duration of antibody after the fall  in the 
temperature was variable.  There appears to be no difference in its 
duration in those with and those without specific treatment.  In the 
treated group, early or late treatment seemed to have no influence on 
its persistence. 
The explanation of the disappearance of antibody in certain cases 
and its persistence in others is not clear.  The presence of an unre- 
solved pneumonia, or such complications as  empyema or pneumo- 
coccus endocarditis, may have been responsible in certain cases, but in 
others no explanation is apparent. 
Relation of Antibody to the Outcome 
Of 35 patients who showed antibody at some time during the course 
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antibody was present at the time of the fall in the temperature in all. 
Of the 6 fatal cases, all were treated, none before the fifth day.  One 
had empyema and pneumococcus  endocarditis and another cardiac and 
renal  complications.  There  were  no obvious  complications in  the 
remaining four.  All 6  had demonstrable antibody to within thirty- 
six hours of death. 
Of 6 patients without protection during the course of the disease 
5 died and 1 recovered.  None were specifically treated.  The patient 
who recovered failed to show antibody during the last three days of 
the disease and when tested five times during a subsequent period of 
twelve days. 
Observations on A gglutinin in Pneumonia 
The behavior of agglutinin was much the same as that of antibody. 
When present during the disease in patients without specific treatment 
it was first demonstrated at the time of the crisis or lysis.  It was 
frequently demonstrated in specifically treated patients earlier than 
would otherwise be expected.  It was present in all but 4 of 27 patients 
at  the  time  of  the  fall  in  temperature.  During  the  post-febrile 
period agglutinin was usually found to persist for a  shorter  period 
than did antibody. 
Value of Tests  for A gglutinin as an Indication of the Presence of Antibody 
during the Course of the Disease 
Inasmuch as  tests  for  agglutinin in  the patient's  blood  are  not 
difficult  to  perform  the  question  arises  whether  the  presence  or 
absence of agg]utinin may be useful as an indication of the presence or 
absence of antibody and the control of dosage of specific serum.  In 
an attempt to answer the question, we have correlated the findings 
with respect to these two substances in 32 patients.  Agglutinin and 
antibody appeared simultaneously in  8.  Agglutinin preceded anti- 
body in 5 cases, in 3 of these by one day and in 2 by two days.  In 
2,  agglutinin was present without antibody at any time during the 
course of the disease.  Of the remaining 17 patients, in 9  antibody 
preceded agglutinin by one day in 3, by two days in 1, by three days in 
4 and by four days in 1.  In 8 patients antibody was present without 
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Agglutinin may be present even in high titer without any demon- 
strable antibody and conversely there may be abundant protective 
substances without demonstrable agglutinin.  In 7 of 32 patients the 
presence of agglutinin if interpreted.as an indication of the presence of 
antibody, would have led to an erroneous conclusion regarding treat- 
ment.  Agglutinin,  therefore,  is  unreliable  as  a  control  of  dosage. 
The clinical aspects of the case seem to us a better means of judging 
the desirable amount of serum and the frequency with which it should 
be administered. 
CONCLUSIONS 
1.  Protective substances  and  agglutinins  were not  demonstrated 
in the blood of patients with pneumonia untreated with serum before 
the fall in the temperature by crisis or lysis. 
2.  Protective substances and agglutinins were frequently demon- 
strated in serum treated patients during the course of the disease. 
3.  Protective substances and agglutinins were usually present at the 
time of the temperature fall in patients  untreated with serum and 
persisted for days or weeks thereafter. 
4.  Protective substances have an important bearing on the outcome. 
A large proportion of those with protection recover and a large propor- 
tion without it die. 
5.  Agglutinin and antibody may appear simultaneously or one may 
precede or be present without the other. 
6.  Tests for agglutinin are unreliable as a control of dosage of specific 
serum. 